AU706594B2 - Treatment of traumatic brain injury - Google Patents

Treatment of traumatic brain injury Download PDF

Info

Publication number
AU706594B2
AU706594B2 AU74900/96A AU7490096A AU706594B2 AU 706594 B2 AU706594 B2 AU 706594B2 AU 74900/96 A AU74900/96 A AU 74900/96A AU 7490096 A AU7490096 A AU 7490096A AU 706594 B2 AU706594 B2 AU 706594B2
Authority
AU
Australia
Prior art keywords
treatment
tetrahydro
tetrazol
ethyl
methylpyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU74900/96A
Other languages
English (en)
Other versions
AU7490096A (en
Inventor
Brian R. Pike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU7490096A publication Critical patent/AU7490096A/en
Application granted granted Critical
Publication of AU706594B2 publication Critical patent/AU706594B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU74900/96A 1995-11-06 1996-11-05 Treatment of traumatic brain injury Ceased AU706594B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK123295 1995-11-06
DK1232/95 1995-11-06
PCT/DK1996/000458 WO1997017074A1 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Publications (2)

Publication Number Publication Date
AU7490096A AU7490096A (en) 1997-05-29
AU706594B2 true AU706594B2 (en) 1999-06-17

Family

ID=8102484

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74900/96A Ceased AU706594B2 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Country Status (18)

Country Link
EP (1) EP0866706A1 (is)
JP (1) JPH11514654A (is)
KR (1) KR19990067353A (is)
AU (1) AU706594B2 (is)
BG (1) BG63150B1 (is)
BR (1) BR9611396A (is)
CA (1) CA2234824A1 (is)
CZ (1) CZ287441B6 (is)
EA (1) EA000531B1 (is)
HU (1) HUP9901051A2 (is)
IS (1) IS4726A (is)
NO (1) NO982036L (is)
NZ (1) NZ321546A (is)
PL (1) PL326490A1 (is)
SK (1) SK58198A3 (is)
TR (1) TR199800801T2 (is)
WO (1) WO1997017074A1 (is)
ZA (1) ZA969320B (is)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013096A1 (es) * 1997-07-01 2000-12-13 Lundbeck & Co As H Sal de adicion de acido maleico de 5-(2-etil-2-h-tetrazol-5-il)-1-metil- 1,2,3,6-tetrahidropiridina, composicion farmaceutica que la contiene, su usoen terapia y metodo de preparacion de la misma.
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives

Also Published As

Publication number Publication date
BG102480A (en) 1999-01-29
EP0866706A1 (en) 1998-09-30
PL326490A1 (en) 1998-09-28
BR9611396A (pt) 1999-07-13
AU7490096A (en) 1997-05-29
CA2234824A1 (en) 1997-05-15
EA000531B1 (ru) 1999-10-28
EA199800434A1 (ru) 1998-10-29
NO982036D0 (no) 1998-05-05
JPH11514654A (ja) 1999-12-14
CZ138998A3 (cs) 1998-10-14
IS4726A (is) 1998-04-27
NZ321546A (en) 2000-12-22
MX9803432A (es) 1998-09-30
TR199800801T2 (xx) 1998-08-21
NO982036L (no) 1998-06-25
SK58198A3 (en) 1998-10-07
WO1997017074A1 (en) 1997-05-15
CZ287441B6 (en) 2000-11-15
KR19990067353A (ko) 1999-08-16
ZA969320B (en) 1997-05-30
BG63150B1 (bg) 2001-05-31
HUP9901051A2 (hu) 2000-03-28

Similar Documents

Publication Publication Date Title
US20050182089A1 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist
HU202108B (en) Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
EP0651642A1 (en) Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
CZ154897A3 (en) Liquid preparation for oral administration
US20080227818A1 (en) Use of saredutant or its pharmaceutically acceptable salts in the treatment of mixed anxiety-depression disorders
US6297262B1 (en) Treatment of schizophrenia and psychosis
AU706594B2 (en) Treatment of traumatic brain injury
US4845115A (en) Method of medical treatment
JP2005532274A (ja) 雄避妊のための非ホルモン的アプローチ
US6610720B2 (en) Method for treating or preventing emesis
US6962921B2 (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
MXPA98003432A (en) Treatment of traumat cerebral damage
EP0821958A2 (en) Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
JPH1160482A (ja) 性機能改善剤
CN1207039A (zh) 创伤性脑损伤的治疗
JP2001502696A (ja) エイズによる痴呆を処置する方法

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired